Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$3.68 USD

3.68
3,629,417

+0.23 (6.67%)

Updated May 31, 2024 04:00 PM ET

After-Market: $3.70 +0.02 (0.54%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Fate Therapeutics, Inc. [FATE]

Reports for Purchase

Showing records 341 - 360 ( 432 total )

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 341

04/12/2017

Industry Report

Pages: 6

AACR 2017 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 342

04/06/2017

Industry Report

Pages: 13

Healthcare - Cancer in Washington: 2017 AACR Highlights

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 343

04/06/2017

Industry Report

Pages: 13

Healthcare - Cancer in Washington: 2017 AACR Highlights

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 344

03/20/2017

Company Report

Pages: 6

4Q16: ProTmune and FATE-NK100 Promise a Lively 2017; Lowering PT to $6 on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 345

03/17/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 346

03/17/2017

Company Report

Pages: 6

4Q FY16, Fate Looks Compelling Ahead of Data-Rich Year, Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 347

03/17/2017

Company Report

Pages: 9

ROTH Conference 2017 Takeaways and 4Q16 Results; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 348

02/27/2017

Daily Note

Pages: 4

Fate Adds to iPSC Technology, Expanded Platform Promising Immuno-oncology Play, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 349

12/18/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 350

12/08/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 351

12/07/2016

Company Report

Pages: 10

ASH Presentations Showcase Versatility of Technology Platform

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 352

12/06/2016

Industry Report

Pages: 9

Additional ASH Updates for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 353

11/08/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 354

11/08/2016

Company Report

Pages: 4

3Q16: Rejigging the PROTECT Study May Have Long-term Payoff for ProTmune

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 355

11/08/2016

Company Report

Pages: 9

ProTmune Trial Protocol Amended; Impressive Preclinical ASH Lineup

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 356

11/08/2016

Company Report

Pages: 6

Q3 Financials; ProTmune Study Protocol Amended to Support Potential for Accelerated Approval, Trimming Price Target to $7 (from $8)

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 357

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 358

11/04/2016

Industry Report

Pages: 11

ASH 2016 Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 359

09/22/2016

Company Report

Pages: 24

We are initiating coverage of Fate Therapeutics, Inc. with a Buy rating and a target price of $8

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 360

09/22/2016

Industry Report

Pages: 30

Healthcare - The A to Z of HSCT: Investor?s guide to Hematopoietic Transplant Medicine

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party